Skip to main content

Progress in the development of Reversed Chloroquine molecules as antimalarial therapy


Chloroquine (CQ) resistance in P. falciparum is strongly linked to mutations in the gene pfcrt that gives rise to the protein, PfCRT (P. falciparum chloroquine resistance transporter), located in the parasite's digestive vacuole (DV) membrane [1]. In CQ resistant (CQR) strains, accumulation of CQ is reduced in the DV due to increased efflux [2], relative to CQ sensitive (CQS) malaria.


We have developed a class of molecules, termed Reversed Chloroquine compounds (RCQs), that are hybrids made up of a chloroquine (CQ) like moiety, and a chemosensitizer (Reversal Agent, RA) against CQR in malaria [3]. Subsequent structure-activity relationship (SAR) work showed the RCQ molecular design to be very flexible. Thus, a large variety of RCQ molecules has been constructed that retain the in vitro efficacy against P. falciparum malaria [4].


The RCQ molecules have been shown to have low- to even sub-nanomolar in vitro IC50 values against both CQR and CQS malaria strains. Here we report on an expanded set of RCQ entities. A subset of these drug candidates has been tested in mouse models of malaria, and found to be capable of reducing the parasite burden to below detectable limits; being able to cure by the oral route. Furthermore, RCQ molecules are shown to have enhanced uptake into CQR parasites. Both cytotoxicity and acute toxicity in mice are favorable, as is Ames evaluation of mutagenicity. hERG binding SAR shows that variation in the RCQ structure can be used to minimize potential cardiotoxicity issues.


The RCQ approach remains a strong contender to exceed the advantages that CQ brought to malaria chemotherapy for nearly half a century, before being thwarted by resistance.


  1. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-71. 10.1016/S1097-2765(05)00077-8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA: Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol. 2005, 56: 323-33. 10.1111/j.1365-2958.2005.04556.x.

    Article  CAS  PubMed  Google Scholar 

  3. Burgess SJ, Selzer A, Kelly JX, Smilkstein MJ, Riscoe MK, Peyton DH: A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum. J Med Chem. 2006, 49: 5623-5. 10.1021/jm060399n.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Andrews S, Burgess SJ, Skaalrud D, Kelly JX, Peyton DH: Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum. J Med Chem. 2010, 53: 916-9. 10.1021/jm900972u.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Burgess, S.J., Xu-Kelly, J., Liebmann, K. et al. Progress in the development of Reversed Chloroquine molecules as antimalarial therapy. Malar J 9 (Suppl 2), O6 (2010).

Download citation

  • Published:

  • DOI: